The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.
Sufentanil sublingual tablet system. From rationale of use to clinical practice / Vergari, A., Cortegiani, A., Rispoli, M., Coluzzi, F., Deni, F., Leykin, Y., Luca Lorini, F., Martorano, P.P., Paolicchi, A., Polati, E., Scardino, M., Corcione, A., Giarratano, A., Rossi, M.. - In: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES. - ISSN 1128-3602. - 24:22(2020), pp. 11891-11899. [10.26355/eurrev_202011_23847]
Sufentanil sublingual tablet system. From rationale of use to clinical practice
Coluzzi F.Investigation
;
2020
Abstract
The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.| File | Dimensione | Formato | |
|---|---|---|---|
|
Vergari_Sufentanil_2020.pdf
accesso aperto
Note: https://www.europeanreview.org/article/23847
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
444.5 kB
Formato
Adobe PDF
|
444.5 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
